What is Spyre Therapeutics, Inc.'s common stock?

Spyre Therapeutics, Inc. (SYRE) reported common stock of 400M in Q1 2026.

How has Spyre Therapeutics, Inc.'s common stock changed year-over-year?

Spyre Therapeutics, Inc.'s common stock decreased by 0.0% year-over-year, from 400M to 400M.

What is the long-term trend for Spyre Therapeutics, Inc.'s common stock?

Over 5 years (2020 to 2025), Spyre Therapeutics, Inc.'s common stock has grown at a 856.4% compound annual growth rate (CAGR), from 5K to 400M.

Spyre Therapeutics, Inc. SYRE Common Stock

Common Stock at other companies

Bristol-Myers SquibbBMY

$292M0.0%

Eli LillyLLY

$590M-0.4%

AbbVieABBV

$18M0.0%

TG TherapeuticsTGTX

$160K+0.6%

BridgeBio PharmaBBIO

500M+253,707%

Summit TherapeuticsSMMT

1B0.0%

Other financials

Income statement

See full

Revenue-—

Operating income-$45.6M+14.8%

Net income-$69.0M-54.1%

EPS (diluted)-$0.74-23.3%

Balance sheet

See full

Cash & equivalents$97.2M+100%

Total debt$4.3M-9.6%

Total equity$670.8M+39.0%

Total assets$764.0M+34.1%

Cash flow

See full

Operating cash flow-$57.4M-40.0%

CapEx-—

Free cash flow-$39.4M-26.8%

Valuation

See full

Market cap$7.67B+307%

Profitability

See full

Operating margin-39,428.9%-49,795pp

Net margin-52,939.7%-61,871pp

FCF margin-3,442.8%-3,807pp

Returns & leverage

See full

Return on equity-31.1%-10.7pp

Debt / equity0.1×+0.1×

Current ratio9×+0.9×

Where this comes from

Reported directly by Spyre Therapeutics, Inc. in its filing.

Tagged under the XBRL concept us-gaap:CommonStockSharesAuthorized.

The official record: Spyre Therapeutics, Inc.’s 10-Q, filed May 5, 2026, on SEC EDGAR. View the filing →

Ask your AI about Spyre Therapeutics, Inc.'s common stock.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is Spyre Therapeutics, Inc.'s common stock?: Spyre Therapeutics, Inc. (SYRE) reported common stock of 400M in Q1 2026.
How has Spyre Therapeutics, Inc.'s common stock changed year-over-year?: Spyre Therapeutics, Inc.'s common stock decreased by 0.0% year-over-year, from 400M to 400M.
What is the long-term trend for Spyre Therapeutics, Inc.'s common stock?: Over 5 years (2020 to 2025), Spyre Therapeutics, Inc.'s common stock has grown at a 856.4% compound annual growth rate (CAGR), from 5K to 400M.